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Abstract
We report here the design, development and performance of a novel formulation of liposome- encapsulated
glucocorticoids (GCs). A highly efficient (.90%) and stable GC encapsulation was obtained based on a transmembrane
calcium acetate gradient driving the active accumulation of an amphipathic weak acid GC pro-drug into the intraliposome
aqueous compartment, where it forms a GC-calcium precipitate. We demonstrate fabrication principles that derive from the
physicochemical properties of the GC and the liposomal lipids, which play a crucial role in GC release rate and kinetics.
These principles allow fabrication of formulations that exhibit either a fast, second-order (t1/2 ,1 h), or a slow, zero-order
release rate (t1/2 , 50 h) kinetics. A high therapeutic efficacy was found in murine models of experimental autoimmune
encephalomyelitis (EAE) and hematological malignancies.
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Introduction
Glucocorticoids (GCs) are widely used drugs in treatment of
inflammatory diseases and cancer [1–3]. However, treatments
based on GCs are routinely accompanied by adverse effects
related to their unfavorable pharmacodynamics, unfavorable
pharmacokinetics, and biodistribution. When GCs are given
intravenously or orally, their pharmacokinetics obey first-order
release kinetics [4] with an initial high plasma concentration
followed by rapid exponential clearance. This unfavorable
pharmacokinetics can be overcome by the use of a drug delivery
system (DDS) providing a slow, zero-order release kinetics that,
while keeping plasma drug concentration below toxicity level, will
allow for the drug concentration needed to achieve a therapeutic
effect [5]. Such performance can be obtained by using several
different drug delivery approaches including: transdermal pumps
[6] and xenotransplantation [7], or different types of injectable
nano-particulates (nano-DDS) including polymers [8], and
liposomes [9]. Injectable nano-DDS are advantageous as they
utilize the unique micro-anatomy of the inflamed tissue blood
capillaries, which have gaps between the lining endothelial cells
causing vessel leakiness. Inflamed and cancerous tissues can
discriminate between nano- and micro-particles, as only the nano-
particles can extravasate into these tissues. This size-dependent
‘‘passive targeting’’ to the inflamed and cancerous tissues [10–12]
is the Achilles heel of the disease permitting better treatment of
inflammation and cancer.
Using liposomes encapsulating GCs for treatment of inflamma-
tory diseases was one of the first targets of ‘‘Liposomology’’ and
remained a major goal for over four decades [12,13]. Research on
liposomes encapsulating GCs for cancer treatment was also
performed, however to a much lesser extent [14,15]. Despite the
progress achieved, the challenge of making a stable and efficacious
GC-loaded nanoliposome formulation having slow zero-order
release kinetics was not met.
In order to address this challenge we decided to apply the
strategy of transmembrane ion gradient-driven remote loading of
amphipathic weak acid or base drugs into pegylated nano-
liposomes (nano-sterically stabilized liposomes, referred to as
nSSL). Historically, in our laboratory the remote loading
approach began from the need to achieve a highly efficient and
stable liposomal drug encapsulation that would be stable during
storage and have a long circulation time in the blood. This
approach, which was recently discussed by us in detail for 9
different drugs [16], was applied for remote loading of the
amphipathic weak base anticancer drug doxorubicin [16–20] and
was the basis for the first FDA-approved pegylated nano-
liposomal anticancer drug, Doxil
TM.
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TM (1995), this approach was
successfully employed for additional drugs and agents, in our
laboratory and in those of others [16,21–24].
Overall, from our own experience, we concluded that a
transmembrane ammonium sulfate gradient is most suitable for
stable encapsulation of amphipathic weak bases [16–19,25,26],
while a transmembrane calcium acetate gradient is most suitable
for loading amphipathic weak acids [16,27,28].
The theoretical basis of these nanochemical engines, described
elsewhere [9,18,20], is summarized in Scheme S1, (Supporting
information). The core technology of this approach is that
liposomes are fabricated to exhibit the desired pH and/or ion
gradient by their encapsulation with salts composed of either weak
bases (e.g., ammonium) [16,17] or weak acids (e.g., acetate)
[16,28]. The degree of ionization of these compounds is pH
dependent, and their ionized species (i.e., ammonium and acetate)
have a very low permeability coefficient and octanol-to-buffer
partition coefficient; therefore they either do not, or only very
slowly, permeate the liposome lipid bilayer, while their un-ionized
species have high permeability, as well as octanol-to-buffer
partition coefficient (exemplified by ammonia and acetic acid)
and therefore can diffuse relatively fast across the lipid bilayer and
reach the intraliposome aqueous phase [16,20]. The magnitude of
the intraliposome high/external medium low transmembrane
gradient of such ions is the driving force for remote loading, as
they can be exchanged with amphipathic drugs that are weak acids
or bases. The counterion of the gradient-forming ion (e.g. sulfate
or calcium in the case of ammonium or acetate gradient,
respectively) can be selected so that it will control the state of
aggregation and precipitation/crystallization of the drug–counter-
ion salt in the intraliposome aqueous phase, thereby contributing
to control efficiency and stability of remote loading, as well as drug
release rate at various temperatures [16,18–20,26,28].
It is important to note that the successful application of this
nanochemical engine benefits from the very small trapped aqueous
volume of nanoliposomes (2.21610
5 nm
3 for a 37.5 nm radius
liposome), which supports faster and higher accumulation and
intraliposome precipitation of drug–counterion salt in crystalline
or noncrystalline forms.
Recently, we reported success in using these GC-loaded
nanoliposomes (nSSL-GC) for treatment of an adjuvant- induced
arthritis model in rats [27]. The GCs used there are the
amphipathic weak acid GC pro-drugs methylprednisolone hemi-
succinate sodium salt (MPS) and betamethasone hemisuccinate
sodium salt (BMS). nSSL-GC based on high (.37uC) Tm
‘‘liposome-forming phosphatidylcholines’’ are characterized by
the unique property of being a zero-order, slow drug release DDS,
as shown in vitro in human plasma and inflamed synovial fluid, and
in vivo in the rat’s systemic circulation and inflamed paw [27].
This study focuses on the relevance of the physicochemical
aspects of these nSSL-GC to their superior therapeutic perfor-
mance and it complements our 1995 publication [28], which
describes some basic principles of the remote loading of
amphipathic weak acids using model molecules in vitro.
Results and Discussion
Amphipathic weak acid glucocorticoid prodrugs are
optimal candidates for nSSL remote loading
Most approaches of remote drug loading into liposomes require
the loaded drug to be an amphipathic weak base [9,16,18] or acid
[16,27,28]. An in silico database screening of suitable commercially
available GC candidates for remote loading yielded only water-
soluble weak acid GCs: the GC-succinates (GC-S) and the GC-
Phosphates (GC-P). No GCs that are amphipathic weak bases
were found. Therefore, we chose to study the remote loading
approach driven by the intraliposome-high/extraliposome medi-
um-low calcium acetate transmembrane gradient previously
described by us for the loading of amphipathic weak acids [28]
(described in Scheme S1a, Supporting information).
Efficient remote loading of GCs requires the GC candidate to
have a specific set of physicochemical features. Firstly, the GC
should be fairly water-soluble, and secondly, while present in the
extraliposomal medium, a part of the GC molecule has to be
hydrophobic enough to allow sufficient GC diffusion across the
liposome lipid bilayer in its uncharged form (see Scheme S1b,
Supporting information), while inside the intraliposome aqueous
phase the hydrophobicity/hydrophilicity ratio should be reduced
so that rate of release of GC from the intraliposome aqueous phase
into the external medium will be slowed down. This is achieved
firstly by ionization of the loaded GC, which is enhanced by
precipitation of the loaded GC in the intraliposome aqueous phase
as an insoluble Ca(GC)2 salt. This precipitation is related to the
steroid ring structure and to the nano-intraliposomal aqueous
volume of the nSSL. Another important condition for a successful
formulation is having a high ‘‘energy of activation’’, which is the
slope of the Arrhenius plot [17] that describes the rate of GC
release from nano-liposomes as a function of the reciprocal of the
Kelvin temperature (1/T). Such a high slope enables a sufficient
release at 37uC (needed to achieve efficacy), concomitant with a
minimal release at 2–8uC (to ensure long-term storage shelf life),
both of which were demonstrated for Doxil [17,19].
Both GC acid prodrug families, the succinate and the phosphate
sodium salts, meet the conditions of sufficient water solubility.
However, only the GC-S, represented by MPS, but not the GC-P
,represented by dexamethasone phosphate (DEXP), were shown to
be surface-active, as was demonstrated by the reduction of surface
tension of MPS, but not DEXP (Fig. 1a). In addition, the fact that
for MPS, surface activity dependence on its concentration is
characterized by a biphasic curve indicates that it undergoes self-
association at a critical aggregation concentration (CAC) [29,30],
which is ,4.3 mM (Fig. 1a). The amphipathic weak-acid
characteristic is further supported by the linear pH-dependency
of logD for the pH range of 5–8.5 (Fig. 1b). At pH 5 the logD is 2
and at pH 8.5 the logD is -0.75. DEXP shows no partitioning to
the octanol phase throughout this pH range.
Fig. 2a demonstrates that calcium ions (but not sodium ions)
cause MPS aggregation, whereby characterization of the precip-
itate by XRD analysis shows a clear crystalline nature of
Ca(MPS)2 (Fig. 2b). Thus, we concluded that GC-S are highly
favorable candidates for remote loading via the calcium acetate
transmembrane gradient, while the GC-P are not. This prediction
was supported by the highly efficient loading of MPS compared
with the poor remote loading of betamethasone phosphate (BMP)
(see details below).
Understanding the mechanism of MPS remote loading
In order to demonstrate that MPS is remote loaded by the
mechanism proposed in Scheme S1 (Supporting information)
and in order to optimize this procedure we conducted the
following set of experiments:
(I) We characterized the remote loading mechanism of MPS by
studying in parallel the kinetics of MPS influx (out/in) and acetic
acid and calcium ions efflux (in/out) of the nSSL respectively.
Fig. 3a shows that most of the remote loading occurs during the
first 15 min of incubation, and this encapsulation is paralleled by
an efflux of an almost stoichiometric (,mole per mole) amount of
acetic acid from the nSSL (both molecules when fully dissociated
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published cryo-transmission electron microscopy (Cryo-TEM)
images of nSSL remote loaded with MPS (nSSL-MPS) and nSSL
[27,31] (Fig. 2c), and the nSSL-MPS image indicated that MPS
uptake into the nSSL leads to the appearance of a precipitate in
the intraliposome aqueous phase. The XRD studies conducted
here only strengthen the probability that a crystalline calcium-
MPS complex is formed (probably Ca(MPS)2).
(III) In order to prove the advantages of using a calcium acetate
transmembrane gradient for MPS loading it was compared with
other salts. For this, nSSL (of identical lipid composition) were
hydrated with the following salt solutions: sodium chloride, sodium
acetate, calcium chloride, and calcium acetate. After the hydration
step, nSSL were prepared and remote loaded with MPS as described
in Methods. Fig. 3b clearly shows that for efficient loading there is a
need for both the acetate anions and the calcium cations. This stems
from the findings that nSSL hydrated in either calcium acetate or
sodium acetate show a much better loading efficiency than nSSL
hydrated in calcium chloride or sodium chloride, signifying the
necessity of the acetate anion, while calcium as counterion improves
MPS loading more than sodium as counterion as is proven from
comparing nSSL prepared from lipids hydrated in calcium acetate
and in sodium acetate. Moreover, it is important to note that calcium
(but not sodium) cations induce MPS precipitation (Fig. 2a).
Thus, overall (Figs. 1–3) the ‘‘heart’’ of MPS remote loading by
nSSL exhibiting a calcium acetate transmembrane gradient is
basically an exchange process between MPS and acetate anions,
which is followed by precipitation of a calcium MPS salt in the
intraliposome aqueous phase. The fact that all calcium ions
remain entrapped in the intraliposome aqueous phase during
acetate release, MPS loading, and upon storage points to the
integrity of the liposome membrane under the conditions that the
uncharged acetic acid can diffuse via this membrane.
Comparison of remote loading of MPS with other water-
soluble GCs and with passive loading of MPS
In order to determine if our loading approach is applicableto other
GC-S and to GC-P, we compared remote loading of MPS with two
GC-S, and one representative of the GC-P, BMP. This comparison
included the following GCs: (1) hydrocortisone hemisuccinate (HCS),
characterized by a logD = -0.054 at pH 7.0 [32], having one-fifth
the anti-inflammatory potency of MPS [33]; (2) betamethasone
hemisuccinate (BMS), characterized by a logD = -0.01 at pH 7.0
[32], having five times the anti-inflammatory potency of MPS [33];
(3) MPS logD =0.02 at pH 7.0 [32]; (4) BMP, characterized by a
logD = -4.01 at pH 7.0 [32] having five times the anti-inflammatory
potency of MPS [33]. As expected, from the logD values, all of the
GC-S tried were successfully remote loaded into HSPC/CHOL/
2000-PEG-DSPE nSSL with high encapsulation efficiencies: HCS
100%, BMS 80%, and MPS 96%, while the representative of GC-P,
BMP, showed minimal encapsulation as explained by its lack of
amphipathicity.
We were also interested in comparing remote loading to the
passive loading of MPS. This comparison showed a clear
advantage of the remote loading method, which achieved 40-fold
higher encapsulation efficiency (96% versus 2%) and a 3.2-fold
higher intraliposome MPS concentration for the remote loaded
nSSL-MPS (38 [GC]/[PL] versus 12[GC]/[PL]).
In addition, the actual MPS concentration in the intraliposome
aqueous trapped volume was determined. For this we calculated
the actual trapped volume i.e., ml/mmol PL (Vt). As we proved
above and below, the Ca
2+ ions practically do not leak out of the
nSSL during loading and 4uC storage. Therefore, the concentra-
tion of entrapped Ca
2+ was used to determine the trapped volume.
A value of 1.2 ml/mmol PL was obtained. Therefore, encapsulation
of 14.96 mmol MPS for 34.72 mmol PL calculates into MPS
intraliposome concentration of 358 mM, which means that 90%
of the nSSL acetate was replaced with MPS.
Release kinetics as a function of liposome lipid
composition and bulk medium composition
Having nSSL with a slow but sufficient zero-order MPS release
rate is one of the most important features of a viable nSSL-MPS
formulation (see Introduction). Therefore we studied MPS release
rate from nSSL-MPS as a function of liposome lipid composition
and bulk medium composition at 37uC. This is an expansion of
our previous study [27] where we have shown that nSSL-MPS
when incubated in human plasma and inflamed synovial fluid
results in the controlled release of MPS.
The results presented in Fig. 4a and its inserted Table show the
crucial role that nSSL membrane phosphatidylcholine (PC) species
has on determining kinetic order and release rate of MPS. nSSL
based onhigh-Tm PCs(either HSPC orDSPC) arecharacterized by
similar zero-order release profiles, which translate to similar long t1/
2 (50 h forHSPC and 58 h forDSPC),and toa constantreleaserate
of ,1% of the original MPS load per hour, while the low-Tm
‘‘fluid’’ POPC-based nSSL showed a much faster release rate that is
best described by second-order kinetics, having a t1/2 of 0.87 h
(almost complete MPS release in less than 2 hours).
Fig. 4a and its inserted Table also demonstrate that there is no
appreciable effect of plasma components on the release rates,
which at 37uC are similar in human plasma (t1/2 of 50 h) and in
Figure 1. MPS physicochemical parameters relevant to GC
remote loading. (a)Comparing surface tension of MPS (¤) and DEXP
(%) as a function of GC concentration. (b) Octanol/buffer log
distribution of MPS (using 20 mM HEPES at the specified pH as buffer).
doi:10.1371/journal.pone.0025721.g001
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previous study [27], the release of MPS from nSSL based on
HSPC/CHOL/2000-PEG-DSPE when incubated in human
plasma was neither accompanied by loss of liposome calcium ions
nor by change in liposome size distribution (data not shown),
indicating that MPS release is not a result of a destructive effect on
membrane barrier properties, but rather a controlled release
related to the amphipathic nature of the GC.
The large differences in kinetic order and rate of MPS release at
37uC between nSSL based on the fluid, low-Tm POPC and the
solid, high-Tm HSPC or DSPC for a similar level of remote
loading of MPS (using the same transmembrane calcium acetate
gradient for all 3 formulations) indicate that the nSSL membrane
lipid composition is the main factor that determines the release
profile of the amphipathic weak acid.
These effects can be explained by the level of liposome
membrane ‘‘free volume’’ defects [29,34], which represent the
number of transporting units (Fig. 4b) that determines the kinetic
order and rate of drug release. In the case of solid, high-Tm HSPC
or DSPC-based liquid ordered (LO)-phase, the level of free volume
defectsis low[20,29]resultinginsuperiorbarrier propertiesandlow
adiabatic compressibility [35]. Thus, in nSSL based on high-Tm
PCs the small number of free volume defects becomes saturated
already at low MPS concentration and consequently the system
operates under conditions of Vmax, leading to a slow, zero-order
release. nSSL that are based on the fluid, low-Tm POPC, are
characterized by lipid bilayers having higher compressibility [35].
Under such conditions the LO phase membrane has a much larger
numberoffreevolumedefects(equivalenttohighVmax)that cannot
be saturated by the MPS, and hence release rate does not reach
Figure 2. Calcium-MPS interaction studies. (a) Change of turbidity (OD at 600 nm) of 20 mM MPS solution at pH 7.4 generated by mixing MPS
with different salt solutions: calcium acetate (¤), calcium chloride (&), sodium acetate (m), and sodium chloride (N). (b) X-ray diffraction pattern of
calcium acetate (blue), MPS (red) and calcium-MPS (black) powders. (c) Cryo-TEM images of nSSL (white a) before and (white b) after MPS loading
(reprinted with permission from Langmuir [31] and Arthritis and Rheumatism [27]).
doi:10.1371/journal.pone.0025721.g002
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order, second order (Fig. 4b). A simple way to demonstrate the
difference in the release order kinetics through the LO membrane is
to compare it with the way people escape from a large crowd in a
hall under conditions that the number of available gates is limited to
thesituation that thenumberofavailable gatesis unlimited.Limited
gates are a bottleneck that forces a constant release rate over a long
time period, while in a situation of unlimited gates the rate of
evacuation can be accelerated by rushing the people through the
many gates which, due to their large number, can not be saturated.
Furthermore, for the LO phase-nSSL based on the high-Tm HSPC
or DSPC liposome-forming lipids, a high activation energy for MPS
release (37.8 kcal/mole) was deduced from the large Arrhenius plot
slope (describing release rate in the range of 25–55uC as a function of
the reciprocal of the Kelvin temperature (1/T). The high activation
energy means that it is not easy to increase the number of release sites
(gates). This is an important advantage of this formulation, as it ensures
nSSL-MPS loading stability upon long term storage at 4uCw i t h o u t
compromising the needed slow zero-order release at 37uC. In this
respect, nSSL-MPS behaves similarly to Doxil
TM [16–19].
Pharmacokinetic and biodistribution advantages of nSSL-
MPS
Studies which compare the pharmacokinetics and biodistribu-
tion of MPS as nSSL-MPS and free (non-liposomal) drug were
performed in the acute EAE mouse model. For these studies nSSL
radio-labeled by the non-transferable non-metabolizable
3H-
cholesteryl hexadecyl ether (CE) as a liposome marker were used
in order to follow the fate of both the nano-liposomes and the MPS
drug.
Fig. 5 shows the clear pharmacokinetic advantages that MPS
delivered via nSSL has over non-encapsulated (free) MPS. While
non-encapsulated MPS is rapidly cleared in minutes (t1/2 of
,9 min), encapsulated MPS is cleared in hours (t1/2 of ,12 h).
Table 1 shows the MPS BD nSSL advantages over free (non-
liposomal drug. During the first hour post intravenous (IV)
injection, the liver gets much higher levels of non-encapsulated
(free) MPS than of MPS derived from nSSL-MPS. This suggests
much less GC first-pass metabolism, which is relevant to GC side
effects [2]. At 1 hour post injection the MPS ratio of brain to liver
distribution is 12 times higher than at 0.3 hour for free MPS
(compare 0.006 for free with 0.076 for nSSL-MPS). At 24 h post
injection only MPS derived from nSSL is found in the brain at a
brain to liver ratio of 0.18.
Comparison of pharmacokinetics and biodistribution of nSSL-
MPS in healthy and EAE mice show lack of major differences
(data not shown), with the brain being an exception: the
concentration of MPS at 1 and 6 h post IV injection in the
diseased EAE mice brains was about twice that in the healthy mice
Fig. S1a (Supporting information). A similar increase in brain
nSSL levels was also observed (data not shown) suggesting that
most of the drug reached the brain as liposomal drug (which is also
obvious from data presented in Table 1). This is highly significant
especially since the brain is a difficult organ to reach by ‘‘free’’
drugs and should be more so for particulates. This enhanced
permeability to nano-particulates may be explained by changes in
the vascular system that occurs due to the inflammation typical of
the EAE brain [36,37].
Proof of controlled zero-order, slow drug release of nSSL
in mice. The release rate in vivo is calculated from the time-
dependent reduction in drug/liposomes (MPS/
3H-nSSL) ratio in
blood and tissues. No reduction in this ratio should occur if there is
no drug release, as was well presented by Metselaar et al. [38] for
nanoliposomes passively loaded with the water-soluble prodrug
prednisolone phosphate. This suggests in the latter case that there
is no drug release of the liposomes in vivo. The pharmacokinetic
and biodistribution studies done with the nSSL-MPS clearly
demonstrate in vivo zero- order, slow release kinetics in blood
(Fig. 5) and tissues (Fig. S1c Supporting information), which is
similar to what was found for these nSSL in vitro.
The t1/2 of 17 h determined for the release in vivo in the
bloodstream (Fig. 5) although slow, is 3 time faster than the t1/2 of
50 h found in vitro (Fig. 4a and inserted Table). The reason for
the discrepancy between the in vitro (in test tube) and in vivo (in
mice) t1/2 is not yet clear. It may be related to the fact that the in
vitro results were obtained under static conditions at which the
volume of the extra-liposome medium is constant, while in vivo the
free drug once released to the plasma is further cleared to the
interstitial fluids of other tissues and organs, which enhances the
rate of drug release (this assumption is now under evaluation).
Demonstrating therapeutic efficacy of nSSL-MPS in
animal models
Treatment of proteolipid protein (PLP)-induced acute
EAE. We also studied therapeutic efficacy in the proteolipid
protein (PLP)-induced acute mouse EAE, a routinely used model
for the autoimmune inflammatory neurodegenerative disease
multiple sclerosis [39,40], in which the involvement of
inflammation in the brain enhance the permeability of this
difficult to reach organ.
Figure 3. Studying the kinetics of nSSL acetate release and
MPS encapsulation during nSSL remote loading, and the effect
of intraliposome salt composition on MPS loading. (a)Reduction
in level of extraliposome MPS during remote loading of 20 mM (m) and
6.66 mM MPS (6). Extraliposome acetate increase induced by remote
loading of 6.66 mM MPS (N) and 20 mM MPS (¤). As a control, acetate
release from nSSL with no MPS present in the bulk medium (&). (b)
Effect of intraliposome salt composition on MPS remote loading.
doi:10.1371/journal.pone.0025721.g003
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nanoliposomes are able to reach the inflamed brain [36,37]. In this
regard Schmidt et al. [36], showed that nSSL passively loaded
with the water-soluble GC prodrug prednisolone phosphate have a
fivefold better therapeutic efficacy than an equal dose of free
prednisolone phosphate. The superiority of the liposomes’ based
nano-drug is explained in part by accumulation of the nanolipo-
somes in the diseased CNS. Siegal et al., [41] showed enhanced
permeability of Doxil
TM in a mouse brain tumor model. Namely,
at least in some diseased brains the BBB is partially compromised
to the level it enables penetration of nanoliposomes to the diseased
tissue.
Figure 4. Effect of nSSL lipid compositions and external medium composition on kinetic order and rate of MPS release from nSSL-
MPS at 376C. (a) Release of MPS from nSSL composed of: HSPC/CHOL/2000-PEG-DSPE (55/40/5 mole ratio, DSPC being a high Tm PC) (m) (reprinted
with permission from Arthritis and Rheumatism [27]);DSPC/CHOL/2000-PEG-DSPE (55/40/5 mole ratio), when incubated at 37uC in plasma (¤); nSSL
composed of HSPC/CHOL/2000-PEG-DSPE (55/40/5 mole ratio, HSPC being a high Tm PC), at 37uC in PBS buffer (pH 7.4) (&); nSSL composed of
POPC/CHOL/2000-PEG-DSPE (55/40/5 mole ratio, POPC being a low Tm PC) at 37uC in plasma (%). Inset Table — Calculated release kinetic
parameters. (b) Scheme describing the mechanism of kinetic order and release rate: 1. In nano-liposomes of all lipid compositions (applies to all
liposomes!) used in this study, calcium-MPS salt inside the nano-liposomes is in an intraliposome pH- and temperature-dependent equilibrium (K1)
between its precipitated salt form, and its soluble dissociated and un-dissociated forms. Since salt solubility increases with rise in temperature from
4uCt o3 7 uC thereby shifting the equilibrium to increased level of the dissociated products. 2. MPS dissociates from its calcium salt is in equilibrium
(K2) between its protonated (uncharged) and unprotonated (charged) form. This equilibrium is dependent on K1, as the intraliposome pH, is slightly
alkaline, only a small fraction MPS is in the protonated neutral form. 3. Protonated (uncharged) MPS can transverses the lipid bilayer in both directions
effluxing (k3) and influxing (k-3). The net direction of movement is dependent on various conditions including lipid membrane composition, drug
physicochemical properties (such as partition coefficient and polar to non-polar surface area, pH, gradient, dilution, motion, mixing and others Zucker
et al [16]. For the efflux/influx reactions equilibrium is not reached. The effect of interplay between liposome bilayer lipid composition and the
temperature is mediated by bilayer level of ‘‘free volume’’, as discussed by Stein [34], and reviewed by Barenholz and Cevc [29]. The results described
by Fig 4a clearly demonstrate that for nSSL based on high-Tm PCs (HSPC or DSPC) there is a slow, zero-order kinetics MPS release, while for the nano-
liposomes based on the low-Tm DOPC, release rate is fast, second-order. This difference agrees well with the fact that the low Tm-based nSSL has
much higher level of liposome membrane free volume (for more in depth discussion on this issue see Results section entitled: ‘‘Release kinetics as a
function of liposome lipid composition and bulk medium composition’’).
doi:10.1371/journal.pone.0025721.g004
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protocol referred to as ‘‘pulse therapy’’ [42], in which the MPS IV
administration is repeated until the autoimmune attack is
diminished. Accordingly, we started with IV administration of
50 mg/kg MPS when mild clinical symptoms appeared.
Fig. 6a and its inserted Table demonstrate the superior
therapeutic efficacy of nSSL-MPS over free MPS. Firstly, no
mortality occurred in the nSSL-MPS group of 10 mice, while in
the control and free MPS groups 3 out of 10 mice died. Secondly,
looking at the progress of the clinical score, not only was the
severity of disease of the nSSL-MPS-treated group much lower,
but also recovery from the acute disease attack was much faster.
On day 22 mice of the nSSL-MPS treated group reached a clinical
score of ,0.0 (no clinical symptoms) compared with a clinical
score of 2.5 for the free-MPS-treated mice, and 3.0 for the control
group treated with 5% dextrose.
Thirdly, from the statistical evaluation of the data collected from
this experiment, it is obvious that nSSL-MPS are highly efficacious
in reducing disease severity compared with the control untreated
group, or the group treated with a high dose of free drug [compare
the mean maximal score of 1.9 in the nSSL-MPS group (limp tail
with righting reflex) with the score of 4.3 (early paralysis) for the
group treated with free drug].
Comparison between nSSL-MPS and conventional
multiple sclerosis drugs in the acute EAE model. We also
studied in the same mouse model how the therapeutic efficacy of
our nSSL-MPS treatment compares with treatment by the
clinically used multiple sclerosis drugs Betaferon and Copaxone.
Betaferon (interferon beta-1b) [43], is a bacterial-derived
recombinant cytokine having anti-inflammatory activity. Copax-
one [44] (glatiramer acetate) is a polypeptide composed of amino
acids that mimic amino acids found in the main myelin-sheath
protein. Though the exact therapeutic mechanism of Copaxone is
not clear [45], in multiple sclerosis patients it causes decrease in
relapses and lesions [46].
Fig. 6b and inserted Table demonstrate that Copaxone and
Betaferon exhibit a mild therapeutic efficacy, lowering the mean
burden of disease from 2.5460.22 to 2.0860.25 and 2.0160.22,
respectively, while nSSL-MPS, which lower the mean burden to
0.860.17, was clearly superior.
Therapeutic effect of nSSL-MPS in chronic myelin
oligodendrocyte glycoprotein (MOG) 35–55 peptide-
induced EAE model and its comparison to other clinically
available drugs for multiple sclerosis treatment. The
chronic MOG 35–55 peptide-induced EAE mouse model serves
as another common disease model for multiple sclerosis. Using this
mouse model, we compared the therapeutic efficacy of nSSL-MPS
to two types of interferon-beta (interferon-beta 1b referred to as
Betaferon, and interferon-beta 1a referred to as Avonex.
Fig. 6c and inserted Table demonstrate that the chronic EAE
induced by the MOG protein, which is characterized by milder
clinical features than the PLP-induced EAE (as seen by the low
mean clinical score and lack of mortality for all groups), is also
highly responsive to nSSL-MPS treatment.
A comparison with Betaferon and Avonex shows clear
superiority of the nSSL. While nSSL-MPS is characterized by a
mean burden of disease of 0.4660.01, Betaferon and Avonex are
characterized by a mean burden of disease of 1.5860.13 and
0.9460.12, respectively. In addition, in terms of recorded disease
incidence, nSSL-MPS was also superior, with only 3 incidences,
compared to 9 and 6 for the Betaferon and Avonex groups,
respectively.
Overall, when we summarize the efficacy of the treatment in the
EAE mouse model used by the parameter of ‘‘mean burden of
disease’’, free-MPS has almost no significant effect, while nSSL-
MPS was able to lower the mean burden by 4-fold (Fig. 6a).
These results suggest that only nSSL-MPS, but not standard (non-
liposomal) MPS acts as a disease-modifying drug. In addition,
nSSL-MPS was more efficacious than Copaxone or interferon-
beta 1a/b (Fig. 6b, 6c)
Treatment of GC-sensitive mouse BCL-1/B-cell
leukemia. GCs are also frequently used in cancer treatments
targeting various aspects of the disease. These include
chemotherapy, complementary treatment to chemotherapy, and
supportive palliative treatment for side effects induced by
chemotherapy sessions, such as severe edema generated by
tumors [47]. This type of treatment is applied to many tumor
types irrespective of whether the tumor cells are sensitive or
insensitive to the steroids. Recently, Storm and coworkers [15,48]
described a successful treatment of B6F10 murine melanoma by
nano-liposomes passively loaded with the GC water-soluble
prodrug prednisolone phosphate, where the underlying
mechanism was described as inhibition of angiogenesis [15].
However, a greater therapeutic benefit of GCs is their direct ability
to ameliorate hematological neoplasms by the mechanism of
apoptosis induction [1], which is related to the presence of
additional (to the nuclear receptor) mitochondrial GC receptors in
these tumors [49] . Some relevant human hematological cancers
that involve treatment with GCs are acute lymphoblastic
leukemia, chronic myeloid leukemia, Hodgkin’s lymphoma, non-
Hodgkin’s lymphoma, and multiple myeloma [50].
Figure 5. In vivo pharmacokinetic study in mice of
3H-nSSL-MPS
and of free MPS. Pharmacokinetics of free MPS (¤), MPS of nSSL-MPS
(m),
3H-nSSL of nSSL-MPS (&), and the ratio between encapsulated MPS
and its carrier
3H-nSSL (%).The change in this ratio with time is used as
a method to calculate in vivo MPS release rate from
3H-nSSL-MPS.
doi:10.1371/journal.pone.0025721.g005
Table 1. Accumulation of MPS originating from nSSL-MPS
and of free MPS in the liver and brain of acute EAE-induced
mouse.
Formulation Time (h) Liver
a Brain
a Brain/liver ratio
Free MPS 0.3 112.30 0.36 0.003
Free MPS 24 1.10 0.00 0.000
nSSL-MPS 1 48.82 3.65 0.075
nSSL-MPS 24 3.01 0.54 0.180
a— mg MPS per gram organ.
doi:10.1371/journal.pone.0025721.t001
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25721The current treatment protocols of GCs for hematological
cancers are based on the administration of high GC doses [51].
This is done in order to satisfy the need to completely obliterate
the malignant cells, and to reduce the risk of generating resistance.
However, the unfavorable pharmacokinetics and biodistribution of
GCs are major obstacles to achieving efficacious and nontoxic
treatment. Treatment based on use of nSSL-GC may overcome
these major deficiencies, as the same PK and BD advantages that
were demonstrated in the EAE mouse model should also apply to
the cancers. More importantly, unlike other liposomal GC
formulations, which also improve the pharmacokinetic profile of
GCs, our liposomal formulation has the unique characteristic of a
slow zero-order drug release profile during systemic circulation,
making the GC bio-available not only at the inflamed and/or
tumor tissue [52], but also to the malignant circulating cells, which
will have a much prolonged exposure to the released GC.
This assumption was indeed proven in a BCL-1 B-cell leukemia
mouse model [53] where the efficacy of nSSL-MPS was compared
to non-encapsulated free-MPS. The BCL-1 cell line [53] is
characterized by its high sensitivity to GCs, having an in vitro
growth inhibition (GI50) in the nanomolar range (,4.2 nM).
Fig. 6d shows that while free-MPS at the two doses used
(5 mg/kg BW and 25 mg/kg BW) had almost no therapeutic
effect (survival median of 19 days), the two doses of nSSL-MPS
substantially increased median mice survival (35 days for 5 mg/kg
BW and 47 days for 50 mg/kg BW).
Treatment of non-GC-sensitive J6456 mouse T-cell
lymphoma. In addition to the GC-sensitive experiment
described above, we also tested our nSSL-MPS on a non-GC-
sensitive lymphoma model in order to check whether this
formulation could induce a therapeutic effect that is not the result
of a direct cytotoxicity effect, but rather the result of an anti-
inflammatory effect. For this we used the J6456 mouse T-cell
lymphoma model, which we found to have a GI50 value in the mM
range (,1.13 mM). The survival experiment done (Fig. 6e) shows
that, indeed, the nSSL-MPS had a significant therapeutic effect,
where survival median of the J6456 mouse T-cell lymphoma-
bearing mice increased from 17.5 to 23 days, while free-MPS
treatment had no effect at all (survival median of 16.5 days).
Using nSSL-MPS for tumor treatment. The implication of
treatment of MPS-sensitive and MPS-insensitive mice tumors for
human cancer therapy is that the nSSL-GC may increase the
therapeutic index of GCs in both tumor types, with larger direct
impact for MPS-sensitive tumors. This can have a major impact
on current treatment protocols that combine various
chemotherapeutic drugs [50,51]. Namely, by increasing the
therapeutic index of GCs we might lower the dosage of other
drugs in the treatment protocol and by that lower the overall toxic
effect and perhaps increase the overall therapeutic success of the
treatment regime.
Relevancy of nSSL-MPS nano-drug prototype features to
its performance: Conclusions
The optimal nSSL-MPS prototype developed has the following
features:
1. Liposome (nSSL) membrane lipid composition determines and
controls to a large extent the stability and kinetics (order and
rate) of GC release. This is supported by the release activation
energy (Ea) calculated from the Arrhenius plot of the process. A
high (37.8 kcal/mole) activation energy for nSSL based on
high-Tm PCs (HSPC and DSPC) supports slow, but sufficient
for activity, release at 37uC, concomitantly with minimal
release at 4uC (important in order to achieve an acceptable
product shelf life).
2. MPS is released from the nSSL-MPS due to its amphipathicity
and not due to a ‘‘dumping’’ effect related to damaged or
permeable liposome membrane.
3. MPS release profile resembles that of a few other remotely
loaded substances such as Doxil
TM, vincristine, and topotecan
[16–19,54].
4. Bulk medium components have only a minimal effect on
release kinetics.
5. Overall, the features of the optimized nSSL-MPS described
here result in a high drug to lipid ratio (high MPS level per
liposome), high efficiency of encapsulation, good stability
during 4uC storage, superior pharmacokinetic and biodistribu-
tion, as well as a slow zero-order drug release in vivo. All these
lead to superior therapeutic efficacy in mouse and rat models of
diseases with inflammatory components (rheumatoid arthritis
[27], EAE (this study), and cerebral malaria (Waknine-
Grinberg et al., in preparation) and in two types of mouse
tumor models (the MPS-sensitive BCL-1 B-cell leukemia and
the MPS-insensitive J6456 T-cell lymphoma).
Materials and Methods
Materials
Hydrogenated soybean phosphatidylcholine (HSPC) was ob-
tained from Lipoid KG (Ludwigshafen, Germany). The HSPC has
an iodine value of 3.0, and acyl chain composition of 86% stearic
acid (C18:0) and 13% palmitic acid (C16:0), and less than 1% of
other acyl chains. Its solid-ordered (SO) to liquid-disordered (LD)
phase transition occurs at the temperature of maximum change in
the heat capacity (Tm), 52.5uC [35].1-Palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC) and 1,2-distearoyl-sn-glycero-3-phos-
phocholine (DSPC) were obtained from Avanti Polar Lipids,
Alabaster, AL, USA. Cholesterol (CHOL) (.99% pure) was
obtained from Sigma (St. Louis, MO, USA). N-(carbonyl-
methoxypolyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phos-
Figure 6. Therapeutic activity of nSSL-MPS in mice induced with EAE (multiple sclerosis model) and in a BCL-1 B-cell leukemia mice
animal model (cancer model). (a) Comparison of the therapeutic efficacy of nSSL-MPS and non-liposomal (free) MPS in acute EAE mice model.
SJL/J mice (n=10) were treated by IV injections on days 10, 12, 14 with: nSSL-MPS 50 mg/kg BW (m), free MPS 50 mg/kg BW (¤), and dextrose 5%
(control) (&). (b) Comparison of therapeutic efficacy of nSSL-MPS with clinically available drugs, Copaxone and Betaferon on acute EAE mouse model.
SJL/J mice (n=10) were treated by IV injections on days 8, 11 and 14 with: nSSL-MPS 50 mg/kg BW (m); Copaxone 250 mg( .); Betaferon 2000 units
(N); dextrose 5% (control) (&). (c) Comparison of therapeutic efficacy of nSSL-MPS and two types of interferon- beta on MOG peptide-induced
chronic EAE mouse model. C57Bl/6 mice (n=10) were treated by IV injections on days 12, 14, and 16 with: nSSL-MPS 50 mg/kg BW (m); Avonex 2000
units (.); Betaferon 2000 units (N); dextrose 5% (control) (&). Inset Tables — For all of the above experiments detailed disease-characteristics are
given. (d) Survival curve of mice induced with BCL-1 B-cell leukemia. BALB/c mice (n=10) were IV injected on days 5, 9, 12 and 16 with either free MPS
5 mg/kg BW (m), nSSL-MPS 5 mg/kg BW (N) free MPS 25 mg/kg BW (D dashed line) or nSSL-MPS 50 mg/kg BW (#). The control group (n=6) did not
receive any treatment (&). (e) Survival curve of mice induced with J6456 mouse T-cell lymphoma cells. BALB/c mice (n=10) were IV injected on days
5, 9, 12 and 16 with either free MPS 50 mg/kg BW (m dotted line) or nSSL-MPS 50 mg/kg BW (#). The control group (n=6) did not receive any
treatment (&).
doi:10.1371/journal.pone.0025721.g006
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PEG-DSPE) was obtained from Genzyme Pharmaceuticals, Liestal,
Switzerland, and [
3H]-cholesteryl hexadecyl ether, was obtained
from PerkinElmer, Waltham, MA, USA. EAE immunizing
reagents: heat-killed and dried Mycobacterium tuberculosis was obtained
from Sigma and Bordetella pertussis toxin, from Difco.
Glucocorticoid prodrugs: methylprednisolone succinate sodium
salt (MPS) was obtained from Pfizer (Puurs, Belgium). Dexameth-
asone phosphate sodium salt (DEXP), betamethasone phosphate
sodium salt (BMP), and hydrocortisone succinate sodium salt
(HCS) were obtained from Sigma. Betamethasone hemisuccinate
(BMS) was obtained from Steraloids (Newport, RI, USA).
CopaxoneH was obtained from Teva, Inc. (Petach Tikva, Israel).
BetaferonH (interferon beta-1b) was obtained from Schering-
Plough, Inc. (Kenilworth, NJ, USA). AvonexH (interferon beta-1a)
was obtained from Biogen, Inc. (Cambridge, MA, USA). Highly
pure sterile and pyrogen-free water, of 18.2 ohms resistance, with
very low content of total carbon and inorganic ions, was obtained
using a WaterPro PS HPLC/Ultrafilter Hybrid model, (Labconco,
Kansas City, Mo, USA). This water is referred to as ‘‘highly pure
water’’. All the other chemicals, including buffers, were of
analytical grade or better.
Animals
6–7-week-old female SJL/J, C57Bl/6 and BALB/c mice were
obtained from Harlan Laboratories, Jerusalem, Israel.
Ethical Treatment of Animals
The animals were kept at the Hebrew University Animal
Facility and given food and water ad libitum. Experimental use of
animals was authorized by the Ethics Committee of the Hebrew
University Medical School.
Methods
Surface activity and critical aggregation concentration
(CAC) of ‘‘water-soluble’’ GCs. The surface activity and
amphipathicity of the ‘‘water-soluble’’ GCs was determined from
their effect on aqueous phase surface tension [30,55]. For this, we
measured and compared surface tension of aqueous solutions of
the two GCs (MPS and DEXP) over a broad range of
concentrations using a mtrougeS tensitometer (Kibron, Helsinki,
Finland). Measurements were done using 300 mL aliquots of each
GC solution (all pH 7.4) after calibration and zeroing of the sensor
using highly purified water having a surface tension of 72 dynes/
cm.
Using this method, one can assess if the analyte self-aggregates.
The CAC of such an association is determined from the curve
describing surface tension as a function of GC concentration [29].
For amphiphiles that self-associate, this curve is biphasic, and the
intercept between the two slopes describes the CAC (or critical
micelle concentration, CMC, of micelles) [29,55].
Determination of octanol/buffer distribution coeffici-
ent. Amphipathicity is commonly described by the analyte
octanol/aqueous buffer distribution (D) coefficient test (described
by logD) as a function of the aqueous buffer pH.
MPS and DEXP octanol/aqueous buffer logD’s were deter-
mined by the ‘‘shake flask’’ method [56]. Briefly, to a test tube
containing a solution of 1-octanol/HEPES buffer (1/1 v/v), MPS
or DEXP was added, and the test tube was shaken vigorously for
1 h; then the test tube was centrifuged to separate the octanol
(upper phase) and the buffer (lower phase), followed by
determination of MPS or DEXP concentration in each of the
phases. LogD was calculated as the log of the ratio of the GC
concentration in octanol to that in the buffer.
X-ray diffraction analysis of calcium-MPS powder. X-ray
diffraction (XRD) analysis was performed on MPS powder, calcium
acetate powder, and Ca-MPS powder. A precipitate of Ca-MPS
was obtained by mixing 200 mM calcium acetate with 20 mM
MPS, followed by centrifugation (7000g for 5 min); then the upper
phase was discarded and the precipitate was dried at room
temperature. XRD powder measurements were performed on a
D8 Advance diffractometer (Bruker AXS, Karlsruhe, Germany)
with a goniometer radius 217.5 mm, Go ¨bel mirror parallel-beam
optics, 2u Sollers slits, and 0.2 mm receiving slit. Using CuKa
radiation (l=1.5418 A ˚), XRD patterns were recorded from 2u to
52u 2h (at room temperature) with the following measurement
conditions: tube voltage of 40 kV, tube current of 40 mA, step scan
mode with a step size 0.02u 2h, and counting time of 1s/step. XRD
patterns were analyzed using DiffracPlus software.
Preparation of liposomes exhibiting intraliposome high/
medium low transmembrane calcium acetate gradient. All
lipid compositionsused forthefabrication ofnSSLwerelyophilized,
then hydrated in the desired acetate salt (usually 200 mM calcium
acetate). The fabrication procedure was based on the approach of
Peleg-Shulman et al[57]. Extrusion stepswereperformed abovethe
SO-to-LD phase transition temperature of the liposome-forming
PC(.62uCforHSPCorDSPC-basednSSLand roomtemperature
for POPC-based nanoliposomes). Intraliposomal salt gradient (i.e.,
calcium acetate) was created by dialyzing the nSSL against 5%
dextrose in a few steps overnight at 4uC (4 exchanges including final
overnight stage) leading to a transmembrane gradient .800. Our
final nSSL-MPS are small (mean sizeof 83615 nm SD) unilamellar
vesicles in 5% dextrose, having a unimodal narrow size distribution
and low negative charge (zeta potential of -5mV), which is related to
the hindered charge of pegylated liposomes [58].
nSSL-MPS chemical and physicochemical characteriza-
tion. The concentration of MPS and its hydrolysis products were
quantified using HPLC [59]. nSSL phospholipid (PL) concentration
was quantified using the modified Bartlett procedure [60]. The
concentration of calcium (determined by atomic absorption
spectrometry (AAS)) was used for determination of nSSL trapped
(aqueous) volume. Acetate concentration was determined by a
commercial enzymatic kit (Megazyme International, Wicklow,
Ireland), which we modified to determine total extraliposome
medium, and intraliposome aqueous phase acetate concentrations.
The mean size distributions of nSSL and of nSSL-MPS were
determined by a particle sizer ALV-NIBS/HPPS with ALV-5000/
EPP multiple digital correlator (ALV-Laser Vertriebsgesellschaft
GmbH, Langen, Germany). Zeta potential was determined using
Zetasizer Nano Series ZEN2600F (Malvern Instruments, Malvern,
UK)
Cryo-TEM images and X-ray diffraction studies. Cryo-
TEM studies were performed as described in Schroeder et al [31].
Preparation of nSSL passively loaded with MPS. nSSL
into which MPS was passively loaded were prepared as described
above, except that lipid hydration buffer was composed of
100 mg/mL (201 mM) MPS dissolved in 0.9% NaCl.
Remote loading of other water-solubleGC prodrugs. The
following GC prodrugs were remotely loaded into nSSL exhibiting
a transmembrane calcium acetate gradient: hydrocortisone
succinate sodium salt (HDS), betamethasone hemisuccinate
(BMS), and betamethasone phosphate sodium salt (BMP). Remote
loading forall GCswasdone asdescribed inAvniretal[27].Briefly;
GC of choice was dissolved in 5% dextrose and was added to the
nSSL dispersion. The nSSL-GC mixture was incubated for
20 minutes at 60–65uC (above the 52.5uCT m of hydrogenated
soybean phosphatidylcholine), after which the nSSL-GC mixture
was dialyzed against 5% dextrose at 4uC for overnight.
Nano-Liposomes Remote Loaded with Glucocorticoids
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e25721Release kinetics of MPS at 376C from nSSL-MPS in human
plasma and PBS buffer. nSSL-MPS samples composed of
various defined lipid compositions were incubated at 37uC in either
80% human plasma (60 ml nSSL-MPS / 240 ml human plasma) or
in phosphate buffered saline (PBS, pH 7.4) for periods up to 96 h.
Aliquots were taken from these samples at the desired time points
and analyzed for level of drug released by gel permeation
chromatography, using a Sepharose CL-4B column which
separates well nSSL from non-liposomal (free) MPS. The columns
were equilibrated with 0.9% NaCl and then an aliquot of nSSL-
MPS in the desired medium was loadedon the columns; elutionwas
done using 0.9% NaCl, and fractions of ,1 mL were collected
using a fraction collector. Distribution of liposomes in the different
fractions collected was determined using the fluorescent probe
diphenylhexatriene (DPH), which fluoresces only when present in
hydrophobic milieu [61], as described by London and Feligenson
[62]. Fractions 4–7, which contained the nSSL, were analyzed for
PL concentration, particle size distribution, MPS, MPS derivatives,
and Ca
2+ concentration. Fractions 9–16, which lack nSSL and
contain only low molecular weight components, were analyzed for
MPS and MPS derivatives. The nSSL analysis of size distribution,
when combined with [Ca
2+]/[PL], mole ratio was used to assess
physical integrity of nSSL. The change in [MPS]/[PL] was used to
determine kinetics of MPS release from the nSSL.
Induction of EAE. The following EAE animal models were
used:
Acute EAE — immunization with proteolipid protein [40],
which induces a disease characterized by severe clinical symptoms,
with no relapsing sessions, and Chronic EAE — immunization
with the myelin oligodendrocyte glycoprotein [63], which induces
a milder disease, with relapsing sessions.
1. Acute EAE was induced in 6–7-week-old SJL/J female mice
by subcutaneous injection in the flank of complete Freund’s
adjuvant containing 150 mg of proteolipid protein (PLP) 139–151
peptide, and 200 mgo fMycobacterium tuberculosis. In order to boost
the immune system, 150 ng of Bordetella pertussis toxin was injected
intraperitoneally (IP) immediately and 48 h later. In this EAE
model, clinical signs start to appear on days 8–11 post
immunization, and are maximal at about day 19.
2. Chronic EAE was induced in 6–7-week-old C57Bl/6 female
mice by immunizing in the flank on days 0 and 7 with
subcutaneous injection of complete Freund’s adjuvant containing
300 mg of mouse myelin oligodendrocyte glycoprotein (MOG) 35–
55 peptide and 200 mgo fMycobacterium tuberculosis. In order to
boost the immune system, 500 ng of Bordetella pertussis toxin was
injected IP immediately and 48 h later. In this EAE model, clinical
signs also start to appear on days 8–11 post immunization.
Clinical scoring. The animals were monitored for clinical
signs and were scored according to the following parameters: 0—
Normal behavior, 1—Distal limp tail, 1.5—Complete limp tail,
2—Complete limp tail with righting reflex, 3—Ataxia, 4 —Early
paralysis, 5—Full paralysis, 6—Moribund/death. During the
experiment, animals that exhibited clinical symptoms above
ataxia were given saline as hydration fluid.
InFig. 6 for each groupthe mean daily clinical score is given, andin
the inserted Tables, from the combined data the following statistical
parameters (using Prism 4 software, GraphPad software, San Diego,
CA,USA) are given: mean maximal score, and mean burden of disease
(the mean of all the scores throughout all the days of the experiment).
For mean burden of disease, a Student’s t test was used to determine
statistical significance at p,0.05 by using Prism 4 software.
Induction of BCL-1 mouse B-cell lymphoid leukemia. BCL-
1 B-cell lymphoid leukemia was induced [53] in 6–7-week-old BALB/c
mice by IP injection of 1 million BCL-1 lymphoma cells.
Induction of J6456 mouse T-cell lymphoma. J6456 mouse
T-cell lymphoma was induced [64] in 6–7-week-old BALB/c mice
by IP injection of 1 million J6456 T-cell lymphoma cells.
Pharmacokinetics and biodistribution. SJL/J mice
induced with acute EAE and control mice were injected on day
11 with either free MPS (50 mg/kg BW), or
3H-CE labeled-nSSL-
MPS (50 mg/kg of MPS). At 1, 6, 24, and 48 h sera were
collected, and then for each time point, animals (n=3) were
sacrificed to harvest their organs.
Organs were homogenized (Polytron, Kinematica GmbH,
Germany), and then MPS and its derivatives were extracted
according to Smith (1979) [65]. Radiolabeled samples were tested
for level of liposomal marker (
3H-cholesteryl hexadecyl ether
3H-
CE) in homogenates using a sample oxidizer (Model 307, Packard
Instrument Co., Meriden, CT, USA).
Supporting Information
Scheme S1 Principles and mechanism of nSSL trans-
membrane calcium acetate gradient-driven remote
loading and release mechanisms of amphipathic weak
acids such as MPS. (a) Fabrication stage of nSSL having
transmembrane calcium acetate gradient. Calcium acetate at the
desired concentration is passively loaded into intraliposome
aqueous phase during lipid hydration to form multilamellar
liposomes. This is followed by extrusion to form nSSL. Calcium
acetate is removed from the extraliposome medium by repeated
dialysis resulting in intraliposome high/extraliposome-low calcium
acetate gradient. In the intraliposome aqueous phase: 1. Calcium
acetate is dissociated to calcium cations and acetate anions in a pH
and concentration- dependent manner. The intraliposome Ca
2+
ion concentration in the intraliposome aqueous phase is calculated
as {[Ca
2+]/[PL]} /[trapped volume (ml) / [PL} Ca
2+ and PL were
determined as described in Methods. Trapped volume for more
than ten nSSL-MPS batches was 1.1560.11 ml/mmole PL and
[Ca]/[PL 0.38-to-0.28 mM/mM. This results in an intraliposome
Ca
2+ concentration of ,200 mM and a gradient of calcium
acetate before loading of .800 (Turgeman et al., in preparation).
2. The nonprotonated charged acetate is in pH-dependent
equilibrium with the uncharged protonated acetic acid (pKa =
4.75). 3. Acetic acid (but neither acetate nor calcium ions) can diffuse
across the liposome membrane to the external medium. Indeed, Ca
2+
ion concentration is unaffected by the MPS loading. 4. The release of
acetic acidinduces pH increase in the intraliposome aqueous phase to
the extent that the equilibrium of acetate shifts the reaction to the
direction of the nonprotonated, charged acetate anion, and therefore
release of acetic acid is slowed down or practically stops. The pH
changes were measured using pyranine after correction for the
presence of Ca
2+ ions [66]. (b) Stage of remote loading of
amphipathic weak acid GC prodrugs into nSSL. 1. The products
of (a) (above) are nano-liposomes that have lost a small fraction of
their acetate so they have a small excess of calcium cations balanced
electrostatically by hydroxyl anions, which shifts the intraliposome
pH to be slightly alkaline. Therefore, these preformed liposomes are
‘‘eager’’ to ‘‘pump in’’ the amphipathic weak acid GC (drug-D) from
the extraliposome medium. 2. When an amphipathic weak acid GC
prodrug (i.e., MPS) is added to the extraliposome aqueous medium, it
diffuses into the intraliposome aqueous phase in its protonated (un-
ionized) form. In the alkaline intraliposome aqueous phase (see b1)i t
undergoes deprotonation (ionization). 3. The deprotonated (ionized
DCOO
-) of the weak acid drug, will form a salt with Ca
2+
[Ca(MPS)2], which precipitates due to its high concentration and
low solubility in the nano-aqueous volume of the nano-liposome. 4.
These two processes, the deprotonation of the amphipathicweak acid
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of the intraliposomal pH, thereby reducing the intraliposome pH.
This translates into favorable conditions for the protonation of more
acetic acid, which induces is the repeating and recycling the
conditions described in part a2-to-a4 of this scheme. This
‘‘pumping’’ process can continue until all acetate ions are exchanged
with the loaded amphipathic weak acid (MPS). To ensure loading
stability, the process is stopped before the entire acetate gradient is
utilized. All these steps are well documented in the Results and
Discussion section above.
(TIF)
Figure S1 Time-dependent tissue biodistribution of
MPS originating from nSSL-MPS. (a) The time-dependent
biodistribution of MPS originating from IV administered nSSL-
MPS is shown as a ratio of percent injected dose per gram tissue
for the indicated organs measured at 1, 6, 24, and 48 h post IV
injection. (b). Time-dependent biodistribution of
3H-CE origi-
nating from
3H-nSSL-MPS is shown as a ratio of percent injected
dose per gram tissue for the indicated organs measured at 1, 6, 24,
and 48 h post IV injection. (c) Profile of MPS release from
3H-
nSSL-MPS in selected organs presented as the time-dependent
ratio [% injected dose MPS
(of nSSL-MPS)] / [% injected dose
3H-
CE
(of nSSL-MPS)] at 1, 6, and 24 h post IV injection.
(TIF)
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